Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Acquires 315,457 Shares of Stock

by · The Cerbat Gem

Surrozen, Inc. (NASDAQ:SRZN – Get Free Report) major shareholder Group Gp Lp Column III acquired 315,457 shares of the business’s stock in a transaction that occurred on Thursday, November 13th. The shares were bought at an average price of $12.65 per share, for a total transaction of $3,990,531.05. Following the completion of the purchase, the insider owned 962,718 shares of the company’s stock, valued at approximately $12,178,382.70. This represents a 48.74% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Surrozen Trading Down 1.4%

SRZN traded down $0.18 on Monday, reaching $12.80. The company had a trading volume of 26,247 shares, compared to its average volume of 25,907. The company has a market capitalization of $109.71 million, a P/E ratio of -0.57 and a beta of 0.64. The company has a fifty day moving average of $12.83 and a 200-day moving average of $10.60. Surrozen, Inc. has a one year low of $5.90 and a one year high of $18.17.

Surrozen (NASDAQ:SRZN – Get Free Report) last released its quarterly earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The company had revenue of $0.98 million for the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. Research analysts predict that Surrozen, Inc. will post -8.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Lifesci Capital upgraded Surrozen to a “strong-buy” rating in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $38.50.

Get Our Latest Stock Report on SRZN

Institutional Investors Weigh In On Surrozen

Institutional investors and hedge funds have recently modified their holdings of the stock. Stempoint Capital LP grew its holdings in shares of Surrozen by 185.1% in the 2nd quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock worth $6,138,000 after acquiring an additional 445,713 shares during the last quarter. RA Capital Management L.P. lifted its holdings in shares of Surrozen by 140.3% during the first quarter. RA Capital Management L.P. now owns 679,130 shares of the company’s stock valued at $7,919,000 after purchasing an additional 396,550 shares during the last quarter. 5AM Venture Management LLC acquired a new position in shares of Surrozen in the 1st quarter valued at $3,615,000. Stonepine Capital Management LLC increased its stake in Surrozen by 7.1% in the 2nd quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Surrozen by 21.7% in the 3rd quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after purchasing an additional 47,468 shares in the last quarter. Institutional investors and hedge funds own 66.57% of the company’s stock.

About Surrozen

(Get Free Report)

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Featured Stories